Northwire Canada EditionSaturday, July 11, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Other Routine −

PharmaCielo Announces Intention to Issue Interest Shares

PharmaCielo Dilutes Shareholders to Service Debt as Principal Maturity Looms

By The Northwire Desk — AI Analysis Apr 17, 2026 · 07:31 PCLO · 0.045 Pharmacielo Ltd.
Executive Summary
  • PharmaCielo Ltd. announced an intention to issue approximately 11.15 million common shares ("Interest Shares") on April 17, 2026.
  • The issuance is designed to settle accrued interest of $891,681.85 on outstanding 11% secured debentures.
  • Effective price per share for the transaction is set at $0.08, which is significantly higher than the current market trading price of $0.05.
  • The transaction requires approval from the TSX Venture Exchange and is subject to statutory hold periods under Canadian securities laws.
  • This follows a similar announcement on March 17, 2026, where 12.15 million shares were issued at $0.08 to settle nearly $972k in interest.
  • The company continues to rely on equity issuance rather than cash to service its high-interest debt obligations.
Material Impact
  • The news is classified as Routine - Negative because it confirms a pattern of dilution without operational improvement or principal repayment capability.
  • Issuing shares at $0.08 when the market trades at $0.05 represents significant value transfer from existing shareholders to debenture holders, effectively subsidizing debt service costs through equity dilution.
  • The announcement was anticipated following the February and March 2026 news releases regarding interest share issuances; therefore, it lacks surprise factor but reinforces negative sentiment.
  • The stock price has declined from $0.09 in early February to $0.05 by mid-April, indicating the market is already pricing in this dilution risk and liquidity concerns.
  • While settling interest avoids immediate default on coupon payments, it does not address the principal maturity of the debentures due June 30, 2026, which remains a critical looming risk.
PCLO · Price
Company Overview
  • PharmaCielo Ltd. operates in the cannabis and pharmaceutical sector with a focus on CBD/THC products and GACP-certified dried flower exports.
  • Flagship operations include cultivation and processing facilities in Colombia, with export pipelines targeting Latin America, Brazil, South Africa, Australia, and the EU.
  • The company recently divested its La Margarita property for approximately CAD $8.6 million to repay a Banco Agrario loan and fund debenture payments.
  • Management has stated an aim to achieve profitability in 2026 through cost structure improvements and right-sizing cultivation capacity.
  • Revenue has declined year-over-year, with nine-month revenue dropping from $3.24M in 2024 to $1.818M in 2025, despite improved adjusted EBITDA margins.
Read the original news release →

More from Pharmacielo Ltd.

May 19, 2026 · 07:31

PharmaCielo Settles Debt Interest with Equity Amidst Liquidity Concerns

Other Mar 17, 2026 · 07:31

PharmaCielo Announces the Issuance of Interest Shares

Financings Mar 02, 2026 · 07:31

PharmaCielo Announces 2025 Q3 Results, AGM Details

Earnings Mar 02, 2026 · 07:18

SEDAR Interim Financial Statements

None Feb 17, 2026 · 19:49

Pharmacielo schedules AGM, plans debt settlement

Financings Feb 17, 2026 · 07:46

PharmaCielo Announces Annual General Meeting and Intention to Issue Interest Shares

Financings